GlobeNewswire by notified

Inspirata and Ohio State University Continue to Break Digital Pathology Barriers

Share

Columbus, Ohio

Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics.  Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James)  has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images.  “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC.

 

Inspirata will present the detailed scientific advantages of the world’s largest repository of whole slide images at the upcoming 2019 U.S. and Canadian Academy of Pathologists (USCAP) annual conference in National Harbor March 16-20. In addition to demonstrating its regulatory-cleared digital pathology solutions that are now available in the U.S., Canada and Europe, Inspirata also will be presenting three poster sessions on the first and second day of the conference describing the utility of this massive digital data resource.

“The OSUCCC – James has been recognized for leading the digital diagnostic practice in the U.S. and now we are well positioned to lead pathology research efforts as artificial intelligence and machine learning algorithms are becoming more prevalent in our field,” says Dr. Parwani. “Our unique repository of over 1 million whole slide images of cancer cases is a data gold mine. We now have the data required to empower pathologists to accelerate research and cohort identification.”   Dr. Parwani, MD, PhD, MBA, who leads the digital pathology project for the OSUCCC – James, also serves as Vice Chair and Director of Anatomic Pathology at The Ohio State University College of Medicine Department of Pathology.

“A repository of this scale has not yet been achieved globally.  We are proud to work with the OSUCCC – James in accomplishing this goal and look forward to the rich advancements that this resource will provide the entire pathology and research community” says Inspirata Founder, Dr. Mark Lloyd, PhD. “We are proud to help contribute to one of the world’s largest whole slide image library and look forward to our continued research efforts with the OSUCCC – James  so that together we will continue to have a positive impact on patients. Everyone who has been involved deserve congratulations and thanks.”

About Inspirata, Inc.
Inspirata®, Inc. helps patients fighting cancer, and the clinicians they trust, make every moment matter by delivering the most comprehensive cancer informatics solution available globally today.  Inspirata brings disparate data sources together covering the entire cancer care journey to drive informed care decisions.  Surfacing the critical insights from differing data modalities such as imaging, genomics and textual information, aids clinical oncologists and pathologists to make the best diagnosis and decisions for their patients.  We understand how complex cancer care is. That’s why our comprehensive informatics solution quickly creates actionable insights in workflow—so our clients can deliver the highest quality care at a lower cost. Cancer won’t wait for the data needed to make the right diagnosis, select the best treatment path and accelerate research.  That is why our mission is to create inspired data for clinicians to make inspired care decisions and make every moment matter. 

 For more information, please visit www.inspirata.com or contact info@inspirata.com.

All trademarks used herein are the property of their respective owners.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Equinor vil starte andre transje av tilbakekjøpsprogrammet for aksjer for 202425.4.2024 06:47:33 CEST | Pressemelding

Equinor (OSE: EQNR, NYSE: EQNR) vil etter generalforsamlingen 14. mai 2024 starte andre transje av tilbakekjøpsprogrammet for aksjer for 2024 på inntil 1,6 milliarder USD, som annonsert i forbindelse med selskapets første kvartalsresultat 25. april 2024. Gjennomføring av tilbakekjøp i denne andre transjen er betinget av fornyet styrefullmakt fra generalforsamlingen den 14. mai 2024 og avtale med den norske stat om tilbakekjøp av aksjer. I denne andre transjen av tilbakekjøpsprogrammet for 2024 vil aksjer for inntil 528 millioner USD bli kjøpt i markedet, noe som vil gi en samlet andre transje på inntil 1,6 milliarder USD inkludert aksjer som skal innløses fra den norske stat. Transjen vil avsluttes senest 22. juli 2024. Equinor annonserte på kapitalmarkedsdagen i februar 2024 et toårig tilbakekjøpsprogram for aksjer på totalt 10-12 milliarder USD for 2024-2025, hvorav inntil 6 milliarder USD for 2024, inkludert aksjer som skal innløses fra den norske stat. Tilbakekjøpsprogrammet vil væ

Equinor to commence second tranche of the 2024 share buy-back programme25.4.2024 06:47:33 CEST | Press release

Equinor (OSE: EQNR, NYSE: EQNR) will after the annual general meeting 14 May 2024 commence the second tranche of up to USD 1.6 billion of the share buy-back programme for 2024, as announced in relation with the first quarter results 25 April 2024. Execution of share buy-back under this second tranche is subject to renewal of a board authorisation for share buy-back from the annual general meeting 14 May 2024 and agreement with the Norwegian State regarding share buy-back. In this second tranche of the share buy-back programme for 2024, shares for up to USD 528 million will be purchased in the market, implying a total second tranche of up to USD 1.6 billion including shares to be redeemed from the Norwegian State. The tranche will end no later than 22 July 2024. Equinor announced at the Capital Market Update in February 2024 a two-year share buy-back programme of total USD 10-12 billion for 2024-2025, with up to USD 6 billion for 2024, including shares to be redeemed from the Norwegian

Equinor ASA: Nøkkelinformasjon ved kontantutbytte for første kvartal 202425.4.2024 06:46:29 CEST | Pressemelding

Nøkkelinformasjon ved kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2024. Ordinært utbyttebeløp: 0,35 Ekstraordinært utbyttebeløp: 0,35 Annonsert valuta: USD Siste dag inklusive: 15. august 2024 Ex-dato Oslo Børs: 16. august 2024 Ex-dato New York Stock Exchange: 19. august 2024 Record date (eierregisterdato): 19. august 2024 Betalingsdato: 28. august 2024 Vedtaksdato: 24. april 2024 Øvrig informasjon: Kontantutbytte i NOK per aksje vil bli kommunisert 23. august 2024. Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser og er informasjonspliktig i henhold til verdipapirhandelloven §5-12.

Equinor ASA: Key information relating to cash dividend for first quarter 202425.4.2024 06:46:29 CEST | Press release

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2024. Ordinary cash dividend amount: 0.35 Extraordinary cash dividend amount: 0.35 Announced currency: USD Last day including rights: 15 August 2024 Ex-date Oslo Børs: 16 August 2024 Ex-date New York Stock Exchange: 19 August 2024 Record date: 19 August 2024 Payment date: 28 August 2024 Date of approval: 24 April 2024 Other information: The cash dividend per share in NOK will be communicated 23 August 2024. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

Equinors resultater for første kvartal 202425.4.2024 06:45:00 CEST | Pressemelding

Equinor (OSE: EQNR, NYSE: EQNR) leverte et justert driftsresultat* på 7,53 milliarder USD, og 2,57 milliarder USD etter skatt i første kvartal 2024. Det rapporterte driftsresultatet var 7,63 milliarder USD, og resultatet for perioden var 2,67 milliarder USD. Justert resultat* var 2,84 milliarder USD, noe som ga et justert resultat per aksje* på 0,96 USD. Finansielle resultater og drift God drift og høy produksjonSolide finansielle resultater og kontantstrømSterke resultater fra tradingvirksomheten Strategisk framgang Kraft fra land til Sleipner- og Gudrun-feltene på norsk sokkelNy kraftsalgsavtale tildelt Empire Wind 1Forbedret gassportefølje på land i USA gjennom transaksjon Konkurransedyktig kapitaldistribusjon Ordinært kontantutbytte på 0,35 USD per aksjeFortsatt ekstraordinært kontantutbytte på 0,35 USD per aksje. Andre transje i tilbakekjøpsprogrammet på inntil 1,6 milliarder USDForventet total kapitaldistribusjon i 2024 på 14 milliarder USD. Anders Opedal, konsernsjef i Equinor A

HiddenA line styled icon from Orion Icon Library.Eye